US Patent 8,703,781: Scope, Claims, Expiration, Litigation, and Patent Landscape for Dabrafenib-Trametinib Combination Therapy
US Patent 8,703,781 protects the combination of a BRAF inhibitor and a MEK inhibitor used to treat melanoma, particularly metastatic melanoma with a BRAF V600E mutation. The claimed combination corresponds to dabrafenib, including dabrafenib mesylate, and trametinib, including trametinib dimethyl sulfoxide solvate, the active ingredients in Tafinlar and Mekinist. The patent is a combination and method-of-use patent rather than a basic composition-of-matter patent for either individual drug.
The patent issued on April 22, 2014, from an application claiming priority to a September 30, 2009 filing. Its nominal patent expiration date is September 30, 2030, subject to any applicable patent-term adjustment, terminal disclaimer, or patent-term extension recorded in the official patent and Orange Book records. The claims directly cover the dabrafenib-trametinib combination, pharmaceutical compositions and kits containing both agents, and treatment of melanoma, including BRAF V600E-positive metastatic melanoma.[1]
What drugs and compounds are covered by US Patent 8,703,781?
The patent claims identify the active ingredients by chemical formulas rather than drug names in the claim text supplied. The claimed salts and solvates correspond to the following marketed substances:
| Patent reference |
Drug identity |
Marketed form |
Pharmacologic class |
| Compound of formula (I) |
Trametinib |
Trametinib dimethyl sulfoxide, or trametinib DMSO |
MEK1/2 inhibitor |
| Compound of formula (II) |
Dabrafenib |
Dabrafenib mesylate |
BRAF inhibitor |
| Claimed combination |
Trametinib plus dabrafenib |
Mekinist plus Tafinlar |
Targeted melanoma therapy |
Claim 2 expressly narrows the combination to trametinib in the dimethyl sulfoxide solvate form and dabrafenib in the methanesulfonate form. “Methanesulfonate” is the chemical description of the mesylate salt.
The supplied claim language contains a typographical error in claim 12, which refers to a “BRAT V600E mutation.” The intended reference is BRAF V600E, consistent with claim 11 and the approved indication for the drug combination.
What is the legal scope of the independent claims?
The patent has two principal independent claim groups:
- Combination, kit and pharmaceutical composition claims.
- Therapeutic method claims directed to melanoma.
Claim 1: combination of two defined compounds
Claim 1 covers:
- A compound of formula (I), or a pharmaceutically acceptable salt or solvate; and
- A compound of formula (II), or a pharmaceutically acceptable salt.
The claim does not require a specific dosage, dosing sequence, ratio, route of administration, or formulation. Its central limitation is the presence of both claimed compounds in the same therapeutic combination.
Because the claim uses “comprising,” additional components generally may be present without avoiding the claim. A product or regimen containing the claimed two-drug combination plus other excipients, agents or treatment components could fall within the claim, provided the formula limitations are satisfied.
The most important infringement question is whether the accused compounds match the full chemical definitions of formulas (I) and (II). The supplied text does not reproduce those structural formulas. The commercial identity of the compounds can be inferred from the claimed DMSO solvate and mesylate forms, but the exact claim boundary remains controlled by the formula definitions and their specification-supported interpretation.
Claim 2: specific salt and solvate forms
Claim 2 narrows claim 1 to:
- Trametinib dimethyl sulfoxide solvate; and
- Dabrafenib methanesulfonate.
This claim is more commercially focused than claim 1 because it tracks the marketed pharmaceutical forms. It is relevant to combination tablets, co-packaged products, hospital dispensing and treatment regimens using the approved Tafinlar and Mekinist forms.
A product using a different pharmaceutically acceptable salt or solvate could avoid claim 2 while remaining potentially exposed to claim 1 or another claim, depending on the scope of the formula definitions.
What do the kit and pharmaceutical composition claims protect?
Claim 3: combination kit
Claim 3 covers a kit containing the claimed combination together with a pharmaceutically acceptable carrier or carriers.
The kit claim may reach:
- A co-packaged dabrafenib and trametinib product;
- Separate dosage units sold in a single package;
- A kit containing the active ingredients with instructions or administration components;
- A treatment package containing both drugs and pharmaceutical carriers.
The claim does not necessarily require the active ingredients to be chemically combined in one tablet. A package containing separate tablets or capsules may qualify if it satisfies the claim construction applied by a court.
Claim 6: pharmaceutical composition
Claim 6 covers a pharmaceutical composition containing the combination and a pharmaceutically acceptable diluent or carrier.
This claim is directed to a composition rather than a treatment method. It can create exposure for:
- A fixed-dose combination formulation;
- A liquid, solid or parenteral composition containing both active ingredients;
- A compounded or manufactured composition containing the two claimed drugs;
- A co-formulated product using the claimed salts or solvates.
The claim does not specify a particular release profile, excipient system, particle size, dosage strength or manufacturing process. Those limitations would have to be supplied by another claim or interpreted from the patent specification.
What methods of treatment are protected?
Claims 4 and 5: therapeutic use
Claim 4 covers the combination for use in therapy. Claim 5 narrows the use to cancer treatment.
These claims are broad in disease scope compared with claims 7 through 12. Claim 5 is not expressly limited to melanoma or BRAF-mutant disease, although its enforceability and written-description scope would depend on the patent disclosure and the claim construction applied.
Claim 7: melanoma treatment
Claim 7 covers a method of treating melanoma in a human by administering therapeutically effective amounts of both claimed compounds.
Its key limitations are:
- A human patient;
- Melanoma;
- Administration of both compounds;
- Therapeutically effective amounts.
This claim does not expressly require metastatic disease, a BRAF mutation or a particular administration sequence.
Claim 9: metastatic melanoma
Claim 9 narrows claim 7 to metastatic melanoma. This limitation maps closely to the principal commercial use of the combination at the time of the patent’s development and early approval.
Claim 11: BRAF V600E-mutant melanoma
Claim 11 further limits the melanoma to disease with a BRAF V600E mutation. This is a biomarker-defined method-of-use claim. It is narrower than claim 7 because it requires a particular molecular subtype.
Claim 12: metastatic BRAF V600E-mutant melanoma
Claim 12 combines the two principal disease limitations:
- Metastatic melanoma; and
- BRAF V600E mutation.
The claim is commercially important because dabrafenib selectively inhibits mutant BRAF signaling, while trametinib inhibits downstream MEK signaling. The combination is designed to suppress pathway reactivation and delay resistance relative to BRAF inhibition alone.[2]
How many patents cover the dabrafenib-trametinib combination?
The commercial product is protected by a layered patent estate rather than by US Patent 8,703,781 alone.
| Patent layer |
Subject matter |
Commercial relevance |
| Compound patents |
Dabrafenib chemical structure and related compounds |
Protect the BRAF inhibitor itself |
| Compound patents |
Trametinib chemical structure and related compounds |
Protect the MEK inhibitor itself |
| Salt and solvate patents |
Dabrafenib mesylate and trametinib DMSO |
Protect marketed pharmaceutical forms |
| Formulation patents |
Tablets, dosage forms, excipients and stability |
Can delay or complicate formulation substitution |
| Combination patents |
Dabrafenib plus trametinib |
Protect simultaneous or combined use |
| Method-of-use patents |
Melanoma, metastatic melanoma and BRAF-mutant disease |
Target approved and label-linked treatment |
| Manufacturing patents |
Synthesis, intermediates and crystallization |
Raise process-development and supply-chain barriers |
US 8,703,781 is in the combination and method-of-use layer. It does not replace the individual drug patents. A generic or follow-on manufacturer must analyze the individual dabrafenib and trametinib estates separately from the combination patent.
The practical exposure depends on the proposed launch:
- A dabrafenib-only product may not practice the combination claims.
- A trametinib-only product may not practice the combination claims.
- A product labeled for combination treatment may face method-of-use and combination-patent exposure.
- A co-packaged or fixed-dose product may face composition and kit claims.
- A product that omits the patented indication may still face inducement risk if promotional activity encourages the patented use.
When does US Patent 8,703,781 lose exclusivity?
The patent issued on April 22, 2014, and claims priority to September 30, 2009. Based on the standard US patent-term calculation, the nominal expiration date is September 30, 2030.[1]
| Event |
Date |
| Earliest stated priority |
September 30, 2009 |
| US patent issuance |
April 22, 2014 |
| Nominal expiration |
September 30, 2030 |
| Relevant FDA approvals |
Dabrafenib: 2013; trametinib: 2013; combination: 2014 |
The effective exclusivity date must be verified against the current USPTO patent record and FDA Orange Book listing. Patent expiration is distinct from FDA regulatory exclusivity. A patent may expire after regulatory exclusivity ends, and an Orange Book-listed patent may affect an abbreviated new drug application even when the underlying product has been marketed for years.
What is the Orange Book status of the patent?
US 8,703,781 is relevant to the FDA-listed Tafinlar and Mekinist combination estate because its claims cover the coadministration of dabrafenib and trametinib for melanoma. The patent should be assessed by:
- NDA holder submission;
- Listed drug and NDA number;
- Patent use code;
- Expiration date recorded by FDA;
- Whether the listing covers the product, formulation or method of use;
- Whether an approved label includes the patented use.
Orange Book listing does not itself determine ultimate infringement. It determines whether an applicant must provide a patent certification or, for a method-of-use listing, a section viii statement carving out the patented use.[3]
The likely regulatory significance is greatest for an ANDA seeking approval for:
- Dabrafenib and trametinib combination use;
- A co-packaged combination;
- The metastatic melanoma indication;
- BRAF V600E-mutant melanoma;
- A label that instructs simultaneous administration of both agents.
An applicant seeking approval only for an unclaimed indication may attempt a section viii carve-out. The viability of that strategy depends on the proposed label, promotional conduct, prescribing information and the exact FDA patent-use code.
Which companies are challenging the patent?
No well-established public Paragraph IV litigation record is associated specifically with US 8,703,781 in the supplied materials. The absence of an identified case does not eliminate future risk. A Paragraph IV challenger could target:
- Invalidity for obviousness of combining a BRAF inhibitor with a MEK inhibitor;
- Lack of written description or enablement;
- Lack of novelty;
- Indefiniteness in the formula or treatment limitations;
- Noninfringement based on a different salt, solvate, indication or label;
- Section viii carve-out for non-patented uses.
A challenger would likely need to address both the combination patent and the separate patents covering dabrafenib and trametinib. Avoiding this patent alone would not establish freedom to launch the individual drugs.
Potential litigation theories
The main validity issues are likely to involve the predictability and motivation to combine BRAF and MEK inhibition before the priority date. The patentee would rely on the claimed clinical or pharmacologic benefit of dual pathway inhibition, including improved efficacy or reduced resistance.
The main infringement issues are likely to involve:
- Whether the proposed product contains the claimed compounds;
- Whether the proposed label induces simultaneous use;
- Whether a BRAF-mutant indication is included;
- Whether the product uses the claimed salts or solvates;
- Whether a separate package qualifies as a claimed kit;
- Whether a physician’s expected use is sufficient for method-of-use infringement.
What regulatory milestones affect the patent landscape?
| Regulatory event |
Significance |
| FDA approval of Tafinlar |
Established dabrafenib as an approved BRAF-targeted therapy |
| FDA approval of Mekinist |
Established trametinib as an approved MEK inhibitor |
| FDA approval of Tafinlar plus Mekinist |
Created the commercial combination relevant to US 8,703,781 |
| Label expansion to BRAF V600E/V600K disease |
Increased relevance of biomarker-specific use claims |
| Combination melanoma indications |
Increased potential Orange Book and inducement exposure |
| Later approvals in other cancers |
May affect claim 5 but not necessarily claims limited to melanoma |
The FDA approved dabrafenib and trametinib as individual products in 2013 and approved their combination for unresectable or metastatic melanoma with BRAF V600E or V600K mutations in 2014.[4,5] The regulatory label is important because method-of-use patent enforcement often turns on whether the approved label encourages the patented treatment.
How strong is the patent estate?
US 8,703,781 has meaningful commercial value because it covers the therapeutic pairing used in the marketed regimen rather than an experimental or peripheral formulation. Its strength differs by claim category.
| Claim category |
Relative strength |
Reason |
| Broad combination claim |
Moderate to strong |
Covers the two-drug regimen, but depends on exact formula construction |
| Specific salt/solvate claim |
Stronger for marketed products |
Tracks dabrafenib mesylate and trametinib DMSO |
| Kit claim |
Moderate |
Depends on packaging and interpretation of “combination kit” |
| Composition claim |
Moderate |
Relevant to co-formulated products; less direct against separate products |
| Broad cancer-use claim |
Moderate |
Broad disease scope may face validity and disclosure challenges |
| Melanoma method claim |
Stronger |
Closely aligned with the disclosed clinical use |
| BRAF V600E method claim |
Strong commercial relevance |
Biomarker limitation is specific and label-linked |
| Metastatic BRAF V600E claim |
Strong but narrow |
Closely matches the principal approved use |
The patent’s strongest practical position is against a product or label that expressly combines dabrafenib and trametinib for BRAF-mutant metastatic melanoma. Its weaker positions are likely to involve broad cancer treatment, alternative formulations and products that separate the agents or omit the claimed indication.
What generic launch scenarios exist?
Scenario 1: single-agent dabrafenib launch
A dabrafenib-only ANDA would not ordinarily practice the two-compound combination claims. It would still face dabrafenib compound, salt, formulation and method-of-use patents.
Scenario 2: single-agent trametinib launch
A trametinib-only ANDA would similarly avoid the combination requirement but would face trametinib-specific patents and any label-linked use patents.
Scenario 3: combination label
An ANDA or 505(b)(2) application that expressly instructs use of dabrafenib with trametinib would have the highest exposure to claims 1, 5, 7, 9, 11 and 12.
Scenario 4: section viii carve-out
A company could seek approval for a non-patented indication while removing instructions for the patented melanoma use. This approach would require a label that does not induce the patented use. A carve-out does not remove liability if marketing, distribution or physician instructions effectively promote the patented combination.
Scenario 5: alternative salts or formulations
A different salt, solvate or formulation may avoid claim 2 or claim 6. It would not necessarily avoid claim 1 or the treatment-method claims, which cover pharmaceutically acceptable salts or solvates and administration of the two compounds.
How does this patent compare with competing targeted melanoma estates?
The patent occupies a distinct position from estates covering single-agent BRAF inhibitors such as vemurafenib or encorafenib, and from estates covering MEK inhibitors such as cobimetinib or binimetinib.
| Regimen |
BRAF component |
MEK component |
Combination-estate issue |
| Tafinlar plus Mekinist |
Dabrafenib |
Trametinib |
Covered by the US 8,703,781 combination concept |
| Zelboraf plus Cotellic |
Vemurafenib |
Cobimetinib |
Separate patent estate |
| Braftovi plus Mektovi |
Encorafenib |
Binimetinib |
Separate patent estate |
| BRAF inhibitor alone |
One BRAF inhibitor |
None |
Generally outside the two-compound claims |
The existence of alternative BRAF-MEK combinations does not by itself avoid infringement if a proposed product contains dabrafenib and trametinib. It does, however, create competitive and licensing alternatives for melanoma treatment and may reduce the commercial leverage of any single combination patent after competing regimens mature.
Key Takeaways
- US 8,703,781 is a combination and method-of-use patent for dabrafenib plus trametinib.
- Claim 2 specifically covers dabrafenib mesylate with trametinib dimethyl sulfoxide.
- The patent claims combinations, kits, pharmaceutical compositions and treatment of melanoma.
- Claims 11 and 12 target BRAF V600E-mutant, including metastatic, melanoma.
- The nominal expiration date is September 30, 2030.
- The patent does not by itself replace the separate compound and formulation patents for Tafinlar or Mekinist.
- The highest-risk launch is a co-packaged, fixed-dose or labeled combination product for BRAF-mutant metastatic melanoma.
- A section viii carve-out may be relevant to a single-agent or non-melanoma launch, but it would not automatically eliminate inducement risk.
- No specific Paragraph IV challenge is established by the cited record.
- The patent’s commercial strength is greatest where the proposed product and label directly track the approved dabrafenib-trametinib regimen.
FAQs
Does US 8,703,781 cover dabrafenib alone?
No. The principal claims require both the compound of formula (I) and the compound of formula (II). Dabrafenib-only products are assessed primarily against dabrafenib-specific patents and method-of-use claims.
Does the patent cover a fixed-dose dabrafenib-trametinib tablet?
Potentially. Claims 1 and 6 may reach a fixed-dose composition if it contains the claimed compounds and satisfies the formula and pharmaceutical-carrier limitations. The exact result depends on the structural definitions and formulation facts.
Can a generic use different salts to avoid the patent?
A different salt may avoid the narrower salt-and-solvate claim, but the broader claims expressly include pharmaceutically acceptable salts or solvates. Salt substitution alone may therefore be insufficient.
Is a BRAF V600K indication covered?
The supplied claims expressly identify BRAF V600E, not V600K. A BRAF V600K label may avoid claims 11 and 12, but could remain exposed to broader combination or melanoma claims.
Does patent expiration permit immediate combination commercialization?
Not necessarily. Separate patents, regulatory exclusivity, Orange Book listings and product-specific formulation or method-of-use patents may continue to affect launch timing after US 8,703,781 expires.
References
-
United States Patent and Trademark Office. (2014). US Patent No. 8,703,781, combinations comprising a BRAF inhibitor and a MEK inhibitor. U.S. Department of Commerce.
-
Flaherty, K. T., Infante, J. R., Daǵan, R., Goncalves, A., Kefford, R., Margolin, K., ... Chapman, P. B. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine, 367(18), 1694-1703.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2013). Tafinlar prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2013). Mekinist prescribing information. U.S. Department of Health and Human Services.
